石四药集团(02005.HK)中期纯利增长23.05%至5.48亿港元中期息每股5.0港仙
格隆汇8月26日丨石四药集团(02005.HK)公布，截至2019年6月30日止六个月，实现收益23.26亿港元，同比增长11.14%；毛利14.9亿港元，同比增长12.88%；公司股权持有人应占溢利5.48亿港元，同比增长23.05%；基本每股盈利0.1817港元；拟派中期股息每股5.0港仙。
2019年上半年公司注重强化主要省份市场的渗透率，完成100余家新医院市场的开发工作；注重调整产品结构，加大治疗性输液的销售上量，保证了公司产品的产销两旺，继续成为大输液行业产量和销售额增长最快的公司。
上半年主导产品大输液销售量约7.8亿瓶袋，同比增长约8%，治疗性输液在大输液销售中的占比增长至21.5%，同比增加1.7个百分点。
公告显示，外贸出口销售保持稳定增长，上半年出口销量同比增长13%。完成了甲硝唑氯化钠注射液、乳酸环丙沙星注射液、18AA氨基酸注射液、乳酸钠林格注射液等20个品规在菲律宾、玻利维亚、乌兹别克斯坦、牙买加等6个国家的出口注册工作，并取得注册证书，新增出口国家3个。
药包材方面，江苏博生发挥自身技术优势，积极回应国家药品关联审评审批新政，上半年取得4个丁基胶塞药包材登记号；关注国家医改政策，积极配合药品制剂企业进行注射剂一致性评价，上半年胶塞产品有4家公司10个注射剂品种上报药审中心进行一致性评价。
新产品研发方面，上半年完成注册申报60项，其中一致性评价5项，原辅包关联审评4项；公司共取得仿制药生产批件14个，其中心血管用药盐酸替罗非班氯化钠注射液临床用於治疗急性冠脉综合症，是极具临床推广潜力的治疗药物，将成为公司业绩发展的主要产品；系列腹膜透析液的获批，与公司已有的血液透析产品的组合，将使公司进军透析产品市场，具有良好的市场成长空间；羟乙基淀粉130氯化钠注射液将在血容量和麻醉市场赢得一席之地；氟康唑片50mg及150mg两个规格通过一致性评价，其中，150mg规格是国内首家通过一致性评价的品种，将在未来国家的产品招标中发挥较好的市场潜力。
项目建设方面，公司新建大容量大规格的血液滤过置换液、腹膜透析液等高附加值输液产品生产线，已於5月份取得GMP证书，设计产能2000万袋╱年，现已投入生产运营。
此外，集团药物研发平台、中试及产业化配套专案正加快专案建设进度，建筑主体及配套建、构筑物已全部完成，2019年底前具备使用条件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
